

# Update March 2024: Omico and PrOSPeCT

## About Omico and Precision Oncology

Omico is a national, independent, not-for-profit organisation leading the use of 'precision oncology' to improve outcomes for people with cancers in Australia. We do this by bringing together a unique network of stakeholders to accelerate access to genomic/molecular profiling and facilitate the delivery of genomic cancer medicine clinical trials to thousands of Australians.

Genomic medicine has changed the oncology landscape. Precision oncology uses genomic/molecular profiling to detect unique variations in patients' cancer tumours, enabling us to predict, prevent, diagnose and treat cancer at an individual level. Precision oncology is the future for all cancer treatment and has the potential to increase Australia's cancer survival rates and improve patient outcomes.

Omico's mission is to accelerate and embed the use of precision oncology in our healthcare system, matching a patient's cancer profile to clinical trials conducted locally with new and innovative targeted treatments.

## About PrOSPeCT – the largest oncology genomics initiative in Australia

PrOSPeCT (Precision Oncology Screening Platform Enabling Clinical Trials) is our landmark precision oncology initiative, enabled by public-private funding and partnerships totalling over \$185M, including \$61.2M grant funding from the Australian Government.

By the end of 2025, PrOSPeCT will have provided free genomic profiling to more than 23,000 Australians with advanced or incurable cancers and identified potential matches for patients to clinical trials with new targeted therapies. As part of this process, PrOSPeCT is creating skilled jobs, building Australia's capabilities and infrastructure in cancer research and care, and strengthening our position as a premier destination for precision oncology trials.

Innovative and collaborative initiatives like PrOSPeCT are fundamental to the pursuit of delivering world-class cancer outcomes for all Australians in an affordable, equitable and sustainable way, and ensuring we remain internationally competitive and at the forefront of research and discovery regarding cancer.



Scan the QR code to learn more.  
[omico.com.au](https://omico.com.au)



# PrOSPeCT Progress

PrOSPeCT has had a very successful initial 12 months, delivering health benefits to patients, stimulating foreign investment into local clinical trials, creating jobs, and generating savings to the health system. As at 31 December 2023:

## Growing Jobs



- 99 direct jobs created across Australia – these are highly skilled new jobs in the medical and science sectors working directly on the PrOSPeCT initiative.
- An estimated 590 indirect jobs across Australia – new jobs have been created to support the delivery of PrOSPeCT in a range of industries, including health, administration, pathology, and pharmacy.

## Driving Economic Growth and Savings

- An estimated \$102M in foreign investment has been generated into locally conducted oncology clinical trials.
- The number of patients accessing clinical trials of targeted therapies is increasing. Each patient enrolled in a clinical trial for treatment and care results in savings for Australia's healthcare budget.



## Building Australian Capacity and Capability



- Omico has established a nationally coordinated, accelerated approach to embed company-sponsored trials into the community at scale – a major drawcard for new international investment in the Australian medical research sector. The network has grown to 43 sites in both metro and regional, rural and remote locations, and growth continues.
- 40 traineeships in clinical trial research skills have been taken up through Omico's delivery partner, Praxis. 58% of trainees are from regional areas, and 8% are Indigenous.
- PrOSPeCT is currently directly supporting 35 (and growing), company-sponsored precision oncology trials, with clinical trial sites in every state and territory;
  - \* All trials will be conducted with greater speed and efficiency by leveraging PrOSPeCT's molecular/genomic profiling and network by identifying patients across the country, and identifying suitable clinical trial sites.
  - \* Nine (9) of these trials would not have opened in Australia but for PrOSPeCT.
- PrOSPeCT has grown Australia's sovereign capability and capacity to conduct genomic/molecular profiling and embed it into clinical practice, with 5 pathology providers now operating locally that are NATA-accredited to deliver profiling services for Australians. Previously, genomic profiling in oncology was only available via research or privately funded, and most profiling was conducted offshore.
- Actively building a rich real world data collection, including linkage to external datasets and data enhancements. PrOSPeCT is now working closely with industry partners to provide data to support clinical trials and real world evidence studies.

## Growing Patient Access to Precision Oncology

As at end of February 2024, 3,493 patients (adult and paediatric) have consented to participate in PrOSPeCT, with:

- 60% having already received a molecular oncology report (and further 27% in progress).
- 78% who have received a report have had a matched therapy recommendation.
- 39% of consented patients are from remote, rural and regional areas of Australia, and 1.9% are from Indigenous backgrounds.

